Abridge Stock
HealthTechLooking to sell Abridge stock or options?
Abridge has developed a healthcare application aimed at enhancing the clarity and comprehension of medical discussions. This app leverages machine learning to provide an audio-based platform that records and summarizes conversations between patients and doctors. By delivering insights and context, it empowers users to adhere to medical advice and stay informed about their health.
Leonis Investissement, NVentures (Santa Clara), Whistler Capital Partners, Pillar VC, Elad Gil, Mayo Clinic, Union Square Ventures, Mana Ventures, ApSTAT Technologies, American College of Cardiology Foundation, University of California, Spark Capital, Irvine, Kaiser Permanente Ventures, LifePoint Health, KdT Ventures, IVP, UPMC Enterprises, Bessemer Venture Partners, Zen Chu, Nvidia, Mass General Brigham, Redpoint Ventures, CVS Health Ventures, Gaingels.
Our available services for this company
*All loans issued by WebBank, member FDICManagement Team
Board Members
Abridge’s stock FAQs
Abridge is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Abridge stock. Depending on Abridge’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Abridge stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Abridge stock in two ways. First, Abridge employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Abridge stock. Note that all transactions in Abridge shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Abridge stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Abridge stock. Typically, shares of private companies like Abridge are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Feb 2024, Abridge is reported to have closed an equity financing in which the investors valued the company at $845M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Abridge shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Abridge is not currently publicly traded, it does not have a ticker symbol.
Abridge has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Abridge is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Abridge shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
